NASHVILLE, Tenn. / Feb 09, 2023 / Business Wire / HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conferences:
March 7, 2023 at 10:25 am EST at the 2023 Raymond James & Associates 44th Annual Institutional Investors Conference at JW Marriott Grande Lakes in Orlando, FL.
March 8, 2023 at 9:50 am EST at the 2023 Cowen and Company 43rd Annual Health Care Conference at the Boston Marriott Copley Place in Boston, MA.
March 14, 2023 at 11:20 am EDT at the Oppenheimer 33rd Annual Virtual Healthcare Conference.
A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.
Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company’s website for the latest information.
All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.
| Last Trade: | US$297.75 |
| Daily Change: | -2.40 -0.80 |
| Daily Volume: | 936,024 |
| Market Cap: | US$75.420B |
October 25, 2024 October 17, 2024 July 23, 2024 April 26, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
